Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

Shaw, Dominick E. and Sousa, Ana R. and Fowler, Stephen J. and Fleming, Louise J. and Roberts, Graham and Corfield, Julie and Pandis, Ioannis and Bansal, Aruna T. and Bel, Elisabeth H. and Auffray, Charles and Compton, Chris H. and Bisgaard, Hans and Bucchioni, Enrica and Caruso, Massimo and Chanez, Pascal and Dahlen, Barbro and Dahlen, Sven-Erik and Dyson, Kerry and Frey, Urs and Geiser, Thomas and Gerhardsson de Verdier, Maria and Gibeon, David and Guo, Yi-ke and Hashimoto, Simone and Hedlin, Gunilla and Jeyasingham, Elizabeth and Hekking, Pieter-Paul W. and Higenbottam, Tim and Horváth, Ildikó and Knox, Alan J. and Krug, Norbert and Erpenbeck, Veit J. and Larsson, Lars X. and Lazarinis, Nikos and Matthews, John G. and Middelveld, Roelinde and Montuschi, Paolo and Musial, Jacek and Myles, David and Pahus, Laurie and Sandström, Thomas and Seibold, Wolfgang and Singer, Florian and Strandberg, Karin and Vestbo, Jorgen and Vissing, Nadja and von Garnier, Christophe and Adcock, Ian M. and Wagers, Scott and Rowe, Anthony and Howarth, Peter and Wagener, Ariane H. and Djukanovic, Ratko and Sterk, Peter J. and Chung, Kian Fan (2015) Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. European Respiratory Journal, 46 (5). pp. 1308-1321. ISSN 1399-3003

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (1MB) | Preview

Abstract

U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.

This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.

Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.

Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of “omic” datasets that are at the core of this systems medicine approach.

Item Type: Article
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine > Division of Respiratory Medicine
Identification Number: http://erj.ersjournals.com/content/46/5/1308
Depositing User: Eprints, Support
Date Deposited: 02 Nov 2016 08:42
Last Modified: 12 Oct 2017 21:45
URI: http://eprints.nottingham.ac.uk/id/eprint/38425

Actions (Archive Staff Only)

Edit View Edit View